CA3081223A1 - Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure - Google Patents

Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure Download PDF

Info

Publication number
CA3081223A1
CA3081223A1 CA3081223A CA3081223A CA3081223A1 CA 3081223 A1 CA3081223 A1 CA 3081223A1 CA 3081223 A CA3081223 A CA 3081223A CA 3081223 A CA3081223 A CA 3081223A CA 3081223 A1 CA3081223 A1 CA 3081223A1
Authority
CA
Canada
Prior art keywords
absence
epilepsy
seizure
formula
absence seizure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3081223A
Other languages
English (en)
French (fr)
Inventor
Hye Won Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66540315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3081223(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of CA3081223A1 publication Critical patent/CA3081223A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3081223A 2017-11-14 2018-11-13 Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure Pending CA3081223A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170151248 2017-11-14
KR10-2017-0151248 2017-11-14
PCT/KR2018/013761 WO2019098628A1 (ko) 2017-11-14 2018-11-13 결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
CA3081223A1 true CA3081223A1 (en) 2019-05-23

Family

ID=66540315

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3081223A Pending CA3081223A1 (en) 2017-11-14 2018-11-13 Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure

Country Status (16)

Country Link
US (1) US20200352907A1 (enExample)
EP (1) EP3711758B1 (enExample)
JP (2) JP7258901B2 (enExample)
KR (1) KR102739584B1 (enExample)
CN (1) CN111432812A (enExample)
AU (1) AU2018367729B2 (enExample)
BR (1) BR112020009265A2 (enExample)
CA (1) CA3081223A1 (enExample)
DK (1) DK3711758T3 (enExample)
ES (1) ES2982316T3 (enExample)
FI (1) FI3711758T3 (enExample)
IL (1) IL274428B2 (enExample)
MX (1) MX2020004972A (enExample)
PL (1) PL3711758T3 (enExample)
PT (1) PT3711758T (enExample)
WO (1) WO2019098628A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113052A1 (en) * 2018-09-21 2020-03-26 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation, or treatment of status epilepticus
CN116143717B (zh) * 2021-11-22 2025-05-06 康百达（四川）生物医药科技有限公司 一种氘代氨基甲酸酯化合物及其在医药上的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383764B1 (en) 2000-04-28 2002-05-07 The Regents Of The University Of California Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP)
KR100534556B1 (ko) 2001-10-26 2005-12-08 주식회사 오리엔트바이오 알파１ｇ 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법
EP1707204A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
US8501436B2 (en) * 2009-06-22 2013-08-06 Sk Biopharmaceuticals Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9629853B2 (en) 2014-05-21 2017-04-25 Wisconsin Alumni Research Foundation Uses of ganaxolone
KR102489052B1 (ko) 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
DK3556349T3 (da) 2016-12-14 2022-01-03 Sk Biopharmaceuticals Co Ltd Parenteralt flydende præparat omfattende en carbamatforbindelse
CA3073925A1 (en) 2017-08-31 2019-03-07 Takeda Pharmaceutical Company Limited Treatment of cns conditions

Also Published As

Publication number Publication date
EP3711758B1 (en) 2024-03-27
PL3711758T3 (pl) 2024-07-01
ES2982316T3 (es) 2024-10-15
MX2020004972A (es) 2020-08-24
IL274428A (en) 2020-06-30
IL274428B2 (en) 2023-08-01
US20200352907A1 (en) 2020-11-12
AU2018367729B2 (en) 2024-06-13
KR102739584B1 (ko) 2024-12-06
RU2020119292A3 (enExample) 2022-02-24
WO2019098628A1 (ko) 2019-05-23
DK3711758T3 (da) 2024-04-08
JP2021503010A (ja) 2021-02-04
KR20200074153A (ko) 2020-06-24
JP7578747B2 (ja) 2024-11-06
AU2018367729A1 (en) 2020-05-21
EP3711758A1 (en) 2020-09-23
FI3711758T3 (fi) 2024-05-13
JP2023085469A (ja) 2023-06-20
BR112020009265A2 (pt) 2020-10-20
RU2020119292A (ru) 2021-12-15
PT3711758T (pt) 2024-04-22
EP3711758A4 (en) 2021-08-04
CN111432812A (zh) 2020-07-17
IL274428B1 (en) 2023-04-01
JP7258901B2 (ja) 2023-04-17

Similar Documents

Publication Publication Date Title
JP7588675B2 (ja) 脆弱ｘ症候群、アンジェルマン症候群又はレット症候群を含む発達障害の軽減又は治療のためのカルバメート化合物の使用
JP7578747B2 (ja) 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用
US20240366566A1 (en) Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
AU2017374458B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
EP3556364B1 (en) Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
RU2787771C2 (ru) Применение карбаматного производного для предотвращения, облегчения или лечения малого эпилептического припадка или эпилепсии, проявляющей малый эпилептический припадок
EP3854391B1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
RU2793742C2 (ru) Применение карбаматного соединения для снижения или лечения нарушений развития, включая синдром хрупкой x-хромосомы, синдром ангельмана или синдром ретта
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919

EEER Examination request

Effective date: 20220919

EEER Examination request

Effective date: 20220919

EEER Examination request

Effective date: 20220919